1. Home
  2. NYT vs RGEN Comparison

NYT vs RGEN Comparison

Compare NYT & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New York Times Company (The)

NYT

New York Times Company (The)

HOLD

Current Price

$67.43

Market Cap

9.3B

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$157.84

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYT
RGEN
Founded
1851
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3B
8.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NYT
RGEN
Price
$67.43
$157.84
Analyst Decision
Buy
Buy
Analyst Count
6
10
Target Price
$63.83
$170.90
AVG Volume (30 Days)
1.7M
724.0K
Earning Date
02-04-2026
10-28-2025
Dividend Yield
1.06%
N/A
EPS Growth
21.46
N/A
EPS
2.05
0.03
Revenue
$2,722,033,000.00
$707,890,000.00
Revenue This Year
$11.06
$17.84
Revenue Next Year
$6.86
$12.57
P/E Ratio
$33.13
$6,185.26
Revenue Growth
8.49
11.74
52 Week Low
$44.83
$102.97
52 Week High
$68.48
$182.52

Technical Indicators

Market Signals
Indicator
NYT
RGEN
Relative Strength Index (RSI) 69.27 48.51
Support Level $63.98 $156.31
Resistance Level $68.54 $165.02
Average True Range (ATR) 1.11 4.62
MACD 0.08 -1.36
Stochastic Oscillator 76.86 12.83

Price Performance

Historical Comparison
NYT
RGEN

About NYT New York Times Company (The)

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: